PL1648925T3 - Środki obrazujące na bazie bicyklicznych peptydów - Google Patents

Środki obrazujące na bazie bicyklicznych peptydów

Info

Publication number
PL1648925T3
PL1648925T3 PL04743485T PL04743485T PL1648925T3 PL 1648925 T3 PL1648925 T3 PL 1648925T3 PL 04743485 T PL04743485 T PL 04743485T PL 04743485 T PL04743485 T PL 04743485T PL 1648925 T3 PL1648925 T3 PL 1648925T3
Authority
PL
Poland
Prior art keywords
imaging agents
bicyclic peptide
peptide imaging
compounds
diseases
Prior art date
Application number
PL04743485T
Other languages
English (en)
Inventor
Alan Cuthbertson
Magne Solbakken
Original Assignee
Ge Healthcare As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare As filed Critical Ge Healthcare As
Publication of PL1648925T3 publication Critical patent/PL1648925T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Light Receiving Elements (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nuclear Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL04743485T 2003-07-30 2004-07-21 Środki obrazujące na bazie bicyklicznych peptydów PL1648925T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0317815.9A GB0317815D0 (en) 2003-07-30 2003-07-30 Imaging agents
EP04743485A EP1648925B1 (en) 2003-07-30 2004-07-21 Bicyclic peptide imaging agents
PCT/GB2004/003150 WO2005012335A1 (en) 2003-07-30 2004-07-21 Imaging agents

Publications (1)

Publication Number Publication Date
PL1648925T3 true PL1648925T3 (pl) 2010-02-26

Family

ID=27799463

Family Applications (2)

Application Number Title Priority Date Filing Date
PL04743485T PL1648925T3 (pl) 2003-07-30 2004-07-21 Środki obrazujące na bazie bicyklicznych peptydów
PL379705A PL210122B1 (pl) 2003-07-30 2004-07-21 Oparte na peptydach związki, sposób i zestawy do ich wytwarzania, ich zastosowanie do diagnozowania oraz zawierające je preparaty radiofarmaceutyczne

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL379705A PL210122B1 (pl) 2003-07-30 2004-07-21 Oparte na peptydach związki, sposób i zestawy do ich wytwarzania, ich zastosowanie do diagnozowania oraz zawierające je preparaty radiofarmaceutyczne

Country Status (23)

Country Link
US (2) US7410943B2 (pl)
EP (1) EP1648925B1 (pl)
JP (1) JP4625002B2 (pl)
KR (1) KR101153529B1 (pl)
CN (1) CN1829735B (pl)
AT (1) ATE442379T1 (pl)
BR (1) BRPI0412986A (pl)
CA (1) CA2533321C (pl)
CY (1) CY1109522T1 (pl)
DE (1) DE602004023092D1 (pl)
DK (1) DK1648925T3 (pl)
ES (1) ES2332722T3 (pl)
GB (1) GB0317815D0 (pl)
HU (1) HUP0600230A3 (pl)
IL (1) IL173029A0 (pl)
MX (1) MXPA06001090A (pl)
NO (1) NO20060825L (pl)
NZ (1) NZ544583A (pl)
PL (2) PL1648925T3 (pl)
PT (1) PT1648925E (pl)
RU (2) RU2355702C2 (pl)
SI (1) SI1648925T1 (pl)
WO (1) WO2005012335A1 (pl)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0210886B8 (pt) * 2001-07-10 2021-05-25 Amersham Health As composto, composição farmacêutica, uso de um composto, e, métodos de geração de imagens, de monitoração do efeito do tratamento de um corpo humano ou animal com uma droga para combater uma condição associada com câncer e de tratamento de câncer ou de uma doença relacionada em um corpo humano ou animal
GB0206750D0 (en) * 2002-03-22 2002-05-01 Amersham Plc Radiofluorination methods
NO20033115D0 (no) * 2003-07-08 2003-07-08 Amersham Health As Peptid-baserte forbindelser
US20060182692A1 (en) 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
WO2005058367A2 (en) 2003-12-16 2005-06-30 Nektar Therapeutics Al, Corporation Pegylated small molecules
JP5280682B2 (ja) * 2004-06-16 2013-09-04 ジーイー・ヘルスケア・アクスイェ・セルスカプ ペプチド系化合物
GB0420344D0 (en) 2004-09-14 2004-10-13 Amersham Plc Diagnostic compounds
DE602005025911D1 (de) 2004-11-22 2011-02-24 Ge Healthcare As Kontrastmittel für eine extrazelluläre matrix
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
US8926945B2 (en) 2005-10-07 2015-01-06 Guerbet Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium
WO2007122488A2 (en) * 2006-04-20 2007-11-01 Hammersmith Imanet Limited Radiofluorinated compounds and their preparation
BRPI0720306A2 (pt) 2006-12-14 2014-02-04 Aileron Therapeutics Inc Sistemas de macrociclização da bis-sufidrila
DK2118123T3 (en) 2007-01-31 2016-01-25 Dana Farber Cancer Inst Inc Stabilized p53 peptides and uses thereof
ES2649941T3 (es) 2007-02-23 2018-01-16 Aileron Therapeutics, Inc. Aminoácidos sustituidos para preparar péptidos macrocíclicos unidos a triazol
US8592377B2 (en) 2007-03-28 2013-11-26 President And Fellows Of Harvard College Stitched polypeptides
GB0722650D0 (en) * 2007-11-19 2007-12-27 Ge Healthcare Ltd Novel imaging method
RU2498798C2 (ru) * 2008-01-09 2013-11-20 Моликьюлар Инсайт Фармасьютикалз, Инк. Ингибиторы карбоангидразы iх
JP5399422B2 (ja) * 2008-02-28 2014-01-29 ジーイー・ヘルスケア・リミテッド 市販の安価な化学薬品からのpeg−6成分の合成
GB0814722D0 (en) * 2008-08-12 2008-09-17 Ge Healthcare Ltd Treatment monitoring
AU2009296235A1 (en) * 2008-09-29 2010-04-01 Gilead Sciences, Inc. Combinations of a rate control agent and an A-2-alpha receptor antagonist for use in multidetector computed tomography methods
US9175047B2 (en) 2009-01-14 2015-11-03 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
GB0905438D0 (en) 2009-03-30 2009-05-13 Ge Healthcare Ltd Radiolabelling reagents and methods
GB0910013D0 (en) * 2009-06-10 2009-07-22 Ge Healthcare Ltd PET imaging of fibogenesis
CN102712675A (zh) 2009-09-22 2012-10-03 爱勒让治疗公司 拟肽大环化合物
WO2011084763A1 (en) 2009-12-21 2011-07-14 Ge Healthcare Limited Borosilicate glassware and silica based qma's in 18f nucleophilic substitution: influence of aluminum, boron and silicon on the reactivity of the 18f ion
ES2711526T3 (es) 2010-08-13 2019-05-06 Aileron Therapeutics Inc Macrociclos peptidomiméticos
PE20140636A1 (es) 2010-09-30 2014-06-18 Astrazeneca Ab Conjugado de naloxol-peg cristalino
FR2967671A1 (fr) * 2010-11-24 2012-05-25 Pf Medicament Complexe de technetium 99m en tant qu'outil de diagnostic in vivo des tumeurs cancereuses
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
BR112014020103A2 (pt) 2012-02-15 2018-10-09 Aileron Therapeutics, Inc. macrociclos peptidomiméticos
EP2819688A4 (en) 2012-02-15 2015-10-28 Aileron Therapeutics Inc TRIAZOL AND THIOETHER-COUPLED PEPTIDOMIMETIC MACROCYCLES
WO2014071241A1 (en) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
AU2015320545C1 (en) 2014-09-24 2020-05-14 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
EP3197478A4 (en) 2014-09-24 2018-05-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
EP4245376A3 (en) 2014-10-14 2023-12-13 Novartis AG Antibody molecules to pd-l1 and uses thereof
WO2016154058A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
GB201511036D0 (en) 2015-06-23 2015-08-05 Guy S And St Thomas Hospital Nhs Foundation Trust Imaging method
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2017044633A1 (en) 2015-09-10 2017-03-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of mcl-1
GB201621864D0 (en) * 2016-12-21 2017-02-01 Ge Healthcare Ltd Solid phase conditioning
CN113000001A (zh) * 2021-03-22 2021-06-22 洛阳海惠新材料股份有限公司 一种用于制备pbat的增粘连体反应器
CN113750923A (zh) * 2021-08-30 2021-12-07 桐昆集团浙江恒腾差别化纤维有限公司 一种酯化反应回收系统

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69230525T2 (de) 1991-02-08 2000-06-21 Diatide, Inc. Technetium-99m markierte Polypeptide zur Bildformung
US5981478A (en) * 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
CA2405469C (en) * 2000-04-12 2012-03-20 Amersham Health As Integrin binding peptide derivatives
RU2165266C1 (ru) * 2000-06-28 2001-04-20 Центральный научно-исследовательский рентгенорадиологический институт Способ получения [2-18f]-2-дезоксиглюкозы
AU2001288847A1 (en) * 2000-09-07 2002-03-22 Biosyntema Inc. Conformationally constrained labeled peptides for imaging and therapy
IL141276A0 (en) * 2001-02-05 2002-03-10 Peptor Ltd Backbone cyclized radiolabelled somatostatin analogs
BRPI0210886B8 (pt) * 2001-07-10 2021-05-25 Amersham Health As composto, composição farmacêutica, uso de um composto, e, métodos de geração de imagens, de monitoração do efeito do tratamento de um corpo humano ou animal com uma droga para combater uma condição associada com câncer e de tratamento de câncer ou de uma doença relacionada em um corpo humano ou animal

Also Published As

Publication number Publication date
CA2533321C (en) 2012-09-18
HUP0600230A2 (en) 2007-01-29
JP2007523880A (ja) 2007-08-23
BRPI0412986A (pt) 2006-10-03
US20060193773A1 (en) 2006-08-31
KR101153529B1 (ko) 2012-06-11
CY1109522T1 (el) 2014-08-13
IL173029A0 (en) 2006-06-11
RU2006102324A (ru) 2007-09-20
PT1648925E (pt) 2009-12-10
KR20060090795A (ko) 2006-08-16
SI1648925T1 (sl) 2010-01-29
HK1097278A1 (en) 2007-06-22
US7410943B2 (en) 2008-08-12
GB0317815D0 (en) 2003-09-03
US7811551B2 (en) 2010-10-12
RU2009105640A (ru) 2010-08-27
RU2355702C2 (ru) 2009-05-20
MXPA06001090A (es) 2006-04-24
CN1829735A (zh) 2006-09-06
PL379705A1 (pl) 2006-11-13
ES2332722T3 (es) 2010-02-11
NZ544583A (en) 2009-12-24
EP1648925B1 (en) 2009-09-09
CN1829735B (zh) 2010-05-26
EP1648925A1 (en) 2006-04-26
JP4625002B2 (ja) 2011-02-02
NO20060825L (no) 2006-03-29
PL210122B1 (pl) 2011-12-30
US20080267881A1 (en) 2008-10-30
ATE442379T1 (de) 2009-09-15
CA2533321A1 (en) 2005-02-10
DK1648925T3 (da) 2010-01-04
DE602004023092D1 (de) 2009-10-22
WO2005012335A1 (en) 2005-02-10
HUP0600230A3 (en) 2009-09-28

Similar Documents

Publication Publication Date Title
PL1648925T3 (pl) Środki obrazujące na bazie bicyklicznych peptydów
AU9245601A (en) Peptide-based compounds
MXPA04000173A (es) Compuestos basados en peptidos.
ATE461196T1 (de) Benzodiazepin-cgrp-rezeptor-antagonisten
EA200300441A1 (ru) Ассоциация антагониста рецептора св1 и сибутрамина, содержащие их фармацевтические композиции и их применение для лечения ожирения
JO2355B1 (en) Hereditary calcitonin polypeptide receptor antagonists
NZ521735A (en) Peptide-based compounds, their use as targeting vectors that bind to receptors associated with antiogenesis such as integrin receptors
BR0008688A (pt) Antagonistas de il-18 recombinantes utilizáveis no tratamento de distúrbios mediados por il-18
AP1503A (en) Benzimidazole and pyridylimidazole derivatives as ligands for GABA receptors
TW200510429A (en) Heterocyclic MCHR1 antagonists
MY161834A (en) Substituted diazepan compounds as orexin receptor antagonists
MX2009012579A (es) Antagonistas piridil piperidina del receptor de orexina.
NO20022655D0 (no) <Beta>-2-adrenerge reseptoragonister
UA74443C2 (uk) Ліганди 5-нт рецептора та їх використання
ATE355288T1 (de) Verbindungen und therapeutische methoden
IL171356A (en) Anti-interferon receptor antibody for treatment of inflammatory bowel disease
DE60230683D1 (de) 3,6-disubstituierte azabicyclo-3.1.0 hexan-derivat
MXPA05011233A (es) Vectores peptidicos.
DE60227576D1 (de) 3,6-DISUBSTITUIERTE AZABICYCLO i3.1.0 -HEXANDERIVATIVE ALS ANTAGONISTEN DES MUSCARINREZEPTORS
WO2002081745A3 (en) Genes involved in osteogenesis, and methods of use
TR200103638T2 (tr) IL-8 Reseptör antagonistleri
EP0648762A3 (en) Bicyclic compounds as excitatory amino acid receptor antagonists
MX2009006028A (es) Compuestos basados en peptido radiomarcado y usos de los mismos.